- Home
- KOD vs ASMB Comparison
KOD vs ASMB Comparison
Compare KOD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- ASMB
- Stock Information
- Founded
- KOD 2009
- ASMB 2005
- Country
- KOD United States
- ASMB United States
- Employees
- KOD N/A
- ASMB N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- ASMB Health Care
- Exchange
- KOD Nasdaq
- ASMB Nasdaq
- Market Cap
- KOD 198.4M
- ASMB 198.6M
- IPO Year
- KOD 2018
- ASMB 2010
- Fundamental
- Price
- KOD $10.52
- ASMB $23.82
- Analyst Decision
- KOD Hold
- ASMB Strong Buy
- Analyst Count
- KOD 4
- ASMB 4
- Target Price
- KOD $11.75
- ASMB $38.67
- AVG Volume (30 Days)
- KOD 673.8K
- ASMB 174.5K
- Earning Date
- KOD 08-13-2025
- ASMB 11-06-2025
- Dividend Yield
- KOD N/A
- ASMB N/A
- EPS Growth
- KOD N/A
- ASMB N/A
- EPS
- KOD N/A
- ASMB N/A
- Revenue
- KOD N/A
- ASMB $33,247,000.00
- Revenue This Year
- KOD N/A
- ASMB $12.44
- Revenue Next Year
- KOD N/A
- ASMB N/A
- P/E Ratio
- KOD N/A
- ASMB N/A
- Revenue Growth
- KOD N/A
- ASMB 54.77
- 52 Week Low
- KOD $1.92
- ASMB $7.75
- 52 Week High
- KOD $11.60
- ASMB $27.17
- Technical
- Relative Strength Index (RSI)
- KOD 64.28
- ASMB 52.32
- Support Level
- KOD $8.29
- ASMB $22.50
- Resistance Level
- KOD $9.23
- ASMB $26.14
- Average True Range (ATR)
- KOD 0.98
- ASMB 1.09
- MACD
- KOD -0.16
- ASMB -0.52
- Stochastic Oscillator
- KOD 74.33
- ASMB 28.16
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.